AstraZeneca Gains US OK For Fasenra In Patient-Friendly Form
Levels playing field with GSK's Nucala
The company is keeping up the pressure on GSK, getting approval for self-administration for Fasenra a few months after a similar green light for severe asthma rival Nucala.
You may also be interested in...
Any lingering hopes Novartis had that fevipiprant could become a blockbuster have disappeared and the Swiss major has ended development of the asthma drug after two more trials failed, this time for severe disease.
The company filed an sNDA with the US FDA for the triple combination, hoping to expand its current COPD indication to also include asthma.
The company's severe asthma drug Fasenra has demonstrated its effectiveness in a Phase II trial for hypereosinophilic syndrome, a group of rare disorders which can cause progressive organ damage.